克罗恩病患者体内鹅去氧胆酸向熊去氧胆酸的转化
Transformation of chenodeoxycholic acid to ursodeoxycholic acid in patients with Crohn's disease.
作者信息
Miwa H, Yamamoto M, Nishida T, Yao T
出版信息
Gastroenterology. 1986 Mar;90(3):718-23. doi: 10.1016/0016-5085(86)91128-5.
In vivo 7 beta-epimerization of chenodeoxycholic acid to ursodeoxycholic acid and the role of 7-ketolithocholic acid as an intermediate in this biotransformation were studied in 11 patients with Crohn's disease and in 5 healthy volunteers. The incorporation of deuterium into biliary ursodeoxycholic acid and 7-ketolithocholic acid was determined by computed gas chromatography-mass fragmentography after ingestion of a dideuterated chenodeoxycholic acid, chenodeoxycholic-11,12-d2 acid. The incorporation of deuterium into ursodeoxycholic acid increased to a peak level at 48 h in the patients with Crohn's disease, but was delayed in healthy volunteers. In 8 patients and 2 healthy controls there were small amounts of 7-ketolithocholic acid in bile. The incorporation of deuterium into 7-ketolithocholic acid was confirmed in only 2 patients and the peak level was noted at 48 h. These observations suggest that 7-ketolithocholic acid is an intermediate of this biotransformation in patients with Crohn's disease.
在11例克罗恩病患者和5名健康志愿者中，研究了鹅去氧胆酸在体内7β-表异构化为熊去氧胆酸以及7-酮石胆酸作为这种生物转化中间体的作用。在摄入二氘代鹅去氧胆酸（鹅去氧胆酸-11,12-d2酸）后，通过计算机气相色谱-质谱碎片分析法测定胆汁中熊去氧胆酸和7-酮石胆酸的氘掺入情况。在克罗恩病患者中，熊去氧胆酸的氘掺入在48小时达到峰值水平，但在健康志愿者中有所延迟。在8例患者和2名健康对照者的胆汁中存在少量7-酮石胆酸。仅在2例患者中证实了7-酮石胆酸的氘掺入，峰值水平出现在48小时。这些观察结果表明，7-酮石胆酸是克罗恩病患者这种生物转化的中间体。
Zotero 插件